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Original Article
Purpose: For recurrent esophageal cancer after primary definitive radiotherapy, no general treatment guidelines are available. We 
evaluated the toxicities and clinical outcomes of re-irradiation (re-RT) for recurrent esophageal cancer.
Materials and Methods: We analyzed 10 patients with recurrent esophageal cancer treated with re-RT after primary definitive 
radiotherapy. The median time interval between primary radiotherapy and re-RT was 15.6 months (range, 4.8 to 36.4 months). The 
total dose of primary radiotherapy was a median of 50.4 Gy (range, 50.4 to 63.0 Gy). The total dose of re-RT was a median of 46.5 
Gy (range, 44.0 to 50.4 Gy). 
Results: The median follow-up period was 4.9 months (range, 2.6 to 11.4 months). The tumor response at 3 months after the end 
of re-RT was complete response (n = 2), partial response (n = 1), stable disease (n = 2), and progressive disease (n = 5). Grade 5 
tracheoesophageal fistula developed in three patients. The time interval between primary radiotherapy and re-RT was less than 12 
months in two of these three patients. Late toxicities included grade 1 dysphagia (n = 1). 
Conclusion: Re-RT of recurrent esophageal cancer after primary radiotherapy can cause severe toxicity. 
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Introduction
Esophageal cancer is usually an advanced disease at presen-
tation, and is associated with poor prognosis regardless of 
the introduction of effective multimodal treatment regimens. 
The common failure of definitive chemo-radiotherapy is 
locoregional. The local recurrence rate at the first site was 
reported to be approximately 44–61% [1,2]. All patients with 
locoregional recurrence died within 1 year without treatment 
[3]. If recurrence occurs, the 5-year survival rate drops to 
0–11% [4-6]. 
  Few curative or palliative treatment options exist for recu-
rrent or persistent esophageal cancer after primary definitive 
radiotherapy. In patients with locoregional recurrence 
after primary definitive radiotherapy, esophagectomy can 
be considered if resectable and medically operable. The 
rate of salvage esophagectomy in patients treated with 
primary definitive radiotherapy with curative intent was 
reported to be 4–29%. However, a high hospital mortality 
rate was reported (about 8–15%). Long-term survival after 
salvage esophagectomy was related to resection without 
residual tumors (R0). The 5-year survival rate after salvage 
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esophagectomy was reported to be up to 25–35% [3,7]. For 
unresectable or medically inoperable esophageal cancer, best 
supportive care is recommended (including external beam 
radiation therapy, intraluminal brachytherapy, chemotherapy, 
hyperthermia, laser, dilatation, endoscopic mucosal resection, 
and stent insertion) [8,9]. 
  In patients with locoregional recurrence after primary 
definitive radiotherapy, re-irradiation (re-RT) is used with 
caution because of the increased probability of normal 
tissue complications [10]. Few reports exist regarding re-RT 
of recurrent or persistent esophageal cancer after primary 
definitive radiotherapy using external beam or intraluminal 
brachytherapy [10-14]. The results of re-RT of the esophagus 
were somewhat favorable, despite severe toxicities such as 
tracheoesophageal fistula, esophageal perforation, esophageal 
stricture, fatal arterial hemorrhage, and pericardial effusion. 
However, no general treatment guidelines concerning re-RT of 
the esophagus are available. 
  The purpose of this study was to evaluate the toxicities and 
clinical outcomes of re-RT for recurrent esophageal cancer 
after primary definitive radiotherapy. 
Materials and Methods
1. Patient selection
From January 2007 to November 2011, a total of 267 patients 
with esophageal cancer were treated with external beam 
radiotherapy at our institution. Seventeen of the patients 
were re-irradiated at the esophagus. Re-RT of the esophagus 
was determined at a multidisciplinary team conference at 
the Esophageal Cancer Clinic. Of the 17 patients, 3 refused 
salvage surgery at the time of recurrence; 14 were inoperable 
considering the medical condition and disease extent at the 
time of recurrence, so re-RT was chosen as a second treatment 
option. 
  One patient with perigastric lymph node recurrence was 
excluded. Another patient with no follow-up information after 
completion of re-RT was excluded. Five patients with boost 
irradiation were excluded. The total dose of boost irradiation 
was less than 30 Gy in these five patients. Ten patients with re-
RT to the recurrent esophageal cancer after primary definitive 
radiotherapy were analyzed retrospectively. 
  The diagnosis of recurrence (or re-growth) was based 
on tissue biopsy, esophagography, endoscopic gastro-
duodenoscopy (EGD), endoscopic ultrasound (EUS), 18F-fluo-
rodeoxyglucose (18F-FDG) positron emission tomography-
computed tomography (PET-CT), and/or chest CT. A recurrent (or 
re-growing) lesion was defined as a progressive lesion after a 
partial response (PR) or stable disease (SD) treatment response 
with primary radiotherapy or a newly developed lesion after a 
complete response (CR) with primary radiotherapy. 
  The Eastern Cooperative Oncology Group (ECOG) performance 
status and tumor/node/metastasis (TNM) stages (American 
Joint Committee on Cancer [AJCC], 7th edition) were evaluated 
at the time of primary radiotherapy, and re-RT. 
2. Radiotherapy
The total doses of primary radiotherapy and re-RT are listed 
in Tables 1 and 2. Ten patients were re-irradiated with an 
external beam with 6- or 10-MV energy using CT-based three-
dimensional (3D) treatment planning. The re-RT modality 
included a 3D conformal radiotherapy using linear accelerator 
(n = 7) and intensity-modulated radiation therapy using helical 
tomotherapy (n = 3). 
  The target delineations of recurrent esophageal cancer were 
as follows: the recurrent gross tumor lesion was delineated as 
the gross tumor volume (GTV); the clinical target volume (CTV) 
was defined as GTV plus a 1.5- to 2.5-cm margin; and CTV 
plus a 5- to 10-mm margin was defined as the planning target 
volume (PTV). 
  The number of beams at re-RT in the linear accelerator 
was 3–6 (considering the normal organ toxicity). The total 
cumulative dose to the spinal cord was limited not to exceed 
the maximal dose of 45 Gy. However, in some cases, a total 
cumulative dose to the spinal cord greater than 45 Gy was 
accepted, considering the time interval between primary 
radiotherapy and re-RT, and the volume of irradiation. The 
length of the re-irradiated esophagus, which was defined as 
the re-irradiated esophagus receiving greater than or equal to 
90% of the prescribed dose, was calculated [11]. 
3. Evaluation of objective response, symptom relief, and 
toxicity
The objective treatment responses were evaluated using 
Response Evaluation Criteria in Solid Tumors (RECIST). The 
follow-up evaluations were performed using endoscopy, 
endoscopy-based biopsy, PET-CT, or CT every 1–3 months. CR 
was defined as the disappearance of all target lesions. PR was 
defined as at least a 30% decrease in the sum of the longest 
diameter (LD) of target lesions, taking as a reference the 
baseline sum of the LD. SD was defined as neither sufficient 
shrinkage to qualify for PR nor sufficient increase to qualify 
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for progressive disease (PD), taking as a reference the smallest 
sum of the LD since the treatment started. PD was defined as 
at least a 20% increase in the sum of the LD of target lesions, 
taking as reference the smallest sum of the LD recorded since 
the treatment started or the appearance of one or more new 
lesions.
  The degree of treatment-related toxicity was evaluated 
by the treating physician and recorded according to the 
Common Terminology Criteria for Adverse Events (CTCAE) ver. 
3.0. Toxicity was defined as acute (during therapy and within 
3 months after therapy) and late (over 3 months after the 
completion of therapy). Local failure was defined as PD of the 
re-irradiated esophagus or regional lymph node. 
4. Statistical analysis
The overall survival and local failure-free survival (LFFS) were 
defined after initiation of re-RT. We did not use Kaplan-Meier 
method for survival analysis because of the small number of 
patients. 
Results
1. Patient characteristics and treatment 
Patient characteristics at diagnosis are shown in Table 1. 
Table 1. Patient characteristics at the time of primary radiotherapy 
Patient 
no.
Age Gender ECOG Pathology
Tumor 
location
Tumor stage RT aim
Dose of RT  
(total/daily, Gy)
Concurrent 
chemotherapy
Treatment 
responsea)
1
2
3
4
5
6
7
8
9
10
55
71
76
76
65
80
82
66
69
85
M
M
M
M
M
M
M
M
M
F
1
1
0
1
1
0
1
1
1
1
SCCa, PD
SCCa, MD
SCCa, MD
SCCa, MD
SCCa, MD
SCCa, MD
SCCa, PD
SCCa, MD
SCCa, MD
SCCa, MD
Upper
Mid/Lo
Upper
Upper
Mid/Lo
Lo
Lo
Upper
Upper
Mid
T4N1M0
T3N0M0
T2N0M0
T3N0M0
T2N1M0
T3N1M0
T4N1M0
T1N0M0
T3N1M0
T2N1M0
Definitive
Definitive
Definitive
Definitive
Neoadj
Neoadj
Definitive
Neoadj
Definitive
Definitive
63.0/1.8
50.4/1.8
54.0/2.0
50.4/1.8
50.4/1.8
54.0/1.8
50.4/1.8
63.0/1.8
50.4/1.8
50.4/1.8
No
TS-1/DDP
5FU/DDP
DDP
TS-1/DDP
5FU/DDP
5FU/DDP
TS-1/DDP
5FU/DDP
5FU/DDP
PR
PR
SD
PR
PR
PR
PR
CR
PR
CR
ECOG, Eastern Cooperative Oncology Group; RT, radiotherapy; SCCa, squamous cell carcinoma; PD, poorly differentiated; MD, moder-
ately differentiated; Upper, upper thoracic esophagus; Mid, middle thoracic esophagus; Lo, lower thoracic esophagus; Neoadj, neoadju-
vant; DDP, cisplatin; 5FU, fluorouracil; PR, partial response; SD, stable disease; CR, complete response.
a)Three months later after end of primary RT. 
Table 2. Patient characteristics at the time of re-irradiation, and treatment results of re-irradiation
Patient 
no.
ECOG
Tumor 
location
Recurred 
stage
Re-RT aim
Dose of RT 
(total/daily, Gy)
CTx with 
re-RT
Intervala) 
(mo)
Treatment 
responseb)
OS LFFS
1
2
3
4
5
6
7
8
9
10
1
2
1
1
1
1
1
1
1
1
Upper
Mid/Lo
Upper
Upper
Mid/Lo
Lo
Lo
Upper
Upper
Mid
T4N1M0
T3N0M0
T1N1M0
T3N0M0
T2N1M0
T3N1M0
T0N1M0
T1N0M0
T3N0M0
T0N1M0
Salvage
Salvage
Salvage
Salvage
Salvage
Salvage
Salvage
Salvage
Salvage
Salvage
48.0/1.2 (bid)
45.0/1.8
45.0/1.8
50.4/1.8
45.0/1.8
45.0/1.8
44.0/2.0
50.4/1.8
50.0/2.0
50.0/2.0
Docet/Ifo
No
5-FU/LV
No
No
No
No
No
Taxol
No
15.6 
  8.8 
17.8 
  4.8 
15.6 
14.2 
12.4 
36.4 
15.5 
18.3 
SD
PD
CR
PD
SD
PR
PD
CR
PD
PD
6.9 
3.2 
14.2 
2.7 
11.2 
5.8 
4.5 
10.4 
2.6 
5.8 
6.5 
1.5 
11.4 
1.3 
11.1 
4.3 
2.3 
10.3 
1.3 
2.1 
Upper, upper thoracic esophagus; Mid, middle thoracic esophagus; Lo, lower thoracic esophagus; Docet, docetaxel; Ifo, ifosfamide; FU, 
fluorouracil; LV, leucovorin; CTx, chemotherapy; re-RT, re-irradiation; OS, overall survival; LFFS, local failure-free survival.
a)Time interval between initial irradiation and re-irradiation. b)Three months later after end of re-RT.
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Nine patients were male. The median age was 73.5 years 
(range, 55 to 85 years). The primary tumor histology was 
squamous cell carcinoma in all patients (n = 10). Eight patients 
had moderately differentiated disease, and two had poorly 
differentiated disease. Clinical stages at primary irradiation 
were as follows: stage I (n = 1), stage II (n = 5), and stage III (n 
= 4). Nine of 10 patients were treated with primary irradiation 
plus concurrent chemotherapy. One patient was treated with 
primary irradiation and sequential chemotherapy. 
  The median interval between the primary radiotherapy and 
re-RT was 15.6 months (range, 4.8 to 36.4 months) (Table 2). 
Re-RT fields were overlapped partially or were within the initial 
irradiation fields. The median longitudinal length of re-RT was 
12.5 cm (range, 9.0 to 16.0 cm). The biologically equivalent 
dose (BED) can be obtained using the following formula: tumor 
cell survival following n fractions, each of dose d,
  BED = nd[1 + d / (α / β)]
  The cumulative dose of radiation was the sum of the total 
dose of primary radiotherapy and re-RT. When the total doses 
of radiation was converted into BED using an α/β ratio of 3 
based on a linear-quadratic model, BED3 ranged from 152.6 to 
181.4 Gy (median, 161.3 Gy). 
  Three of 10 patients were treated with concurrent chemo-
therapy during the course of re-RT. Chemotherapy regimens 
with re-RT were as follows: docetaxel plus ifosfamide (n = 1), 
5-fluorouracil plus leucovorin (n = 1), and taxol (n = 1) (Table 2). 
2. Treatment response
The median follow-up period was 4.9 months (range, 2.6 to 
11.4 months). All 10 patients completed the planned re-RT 
dose. The tumor responses at 3 months after the end of re-RT 
were CR (n = 2), PR (n = 1), SD (n = 2), and PD (n = 5) (Table 2).
  Patient #2 was treated with neoadjuvant concurrent chemo-
radiotherapy (50.4 Gy with a daily dose of 1.8 Gy, initially). At 
3 months after primary radiotherapy, the treatment response 
was PR, although an endoscopic biopsy report showed no 
malignant cell. However, patient #2 refused the definitive 
surgery and treated with six cycles of sequential chemotherapy 
with TS-1/cisplatin. Nine months after primary radiotherapy, 
increased uptake was observed in the primary middle and 
lower thoracic esophagus regions on PET-CT and a progressive 
growing lesion on EUS; however, the biopsy report was free of 
tumors. This lesion was re-irradiated with a total dose of 45 
Gy with a daily dose of 1.8 Gy. Tracheoesophageal fistula and 
esophageal perforation developed 1 day before completion 
of re-RT, and pericardial effusion developed 1 month after 
completion of re-RT. Patient #2 died at 3.2 months after 
initiation of re-RT.
  Patient #4 was treated with concurrent chemo-radiotherapy 
(50.4 Gy with a daily dose of 1.8 Gy, initially). At 3 months 
after primary radiotherapy, the treatment response was PR, 
although endoscopic biopsy report was no malignant cell. At 5 
months after primary radiotherapy, there was ulcerofungating 
mass lesion on the upper thoracic esophagus, and the 
biopsy report was squamous cell carcinoma with moderate 
differentiation. This lesion was re-irradiated with a total dose 
of 50.4 Gy with a daily dose of 1.8 Gy. Tracheoesophageal 
fistula and esophageal perforation developed 20 days after 
completion of re-RT, and patient #4 died at 2.7 months after 
initiation of re-RT. 
  Patient #9 was treated with concurrent chemo-radiotherapy 
of 50.4 Gy with a daily dose of 1.8 Gy, initially. At 3 months 
after primary radiotherapy, the treatment response was PR. At 
15 months after primary radiotherapy, a progressive lesion was 
found on the primary site. This lesion was re-irradiated with 
concurrent chemotherapy, a total dose of 50.0 Gy with a daily 
Table 3. Acute toxicities (within 3 months after the end of re-irradiation)
Patient no. Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
1
2
3
4
5
6
7
8
9
10
Fatigue
Fatigue, nausea
Dysphagia
-
Anorexia
-
-
-
-
-
Esophagitis, dysphagia
Esophagitis, dysphagia
-
Anemia
-
Anorexia
-
Esophagitis
Esophagitis
Dysphagia
-
TP, anemia, neutropenia
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Eso Perf, TEF
-
Eso Perf, TEF
-
-
-
-
Eso Perf, TEF
-
TP, thrombocytopenia; Eso Perf, esophageal perforation; TEF, tracheoesophageal fistula. 
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dose of 2.0 Gy. Tracheoesophageal fistula developed 3 days 
after completion of re-RT. Aspiration pneumonia and lung 
abscess developed sequentially thereafter. Patient #9 died at 2.6 
months after initiation of re-RT. 
3. Toxicity
Acute toxicities included grade 3 hematologic disorder (n = 1) 
and grade 5 esophageal perforation, tracheoesophageal fistula 
(n = 3) (Table 3 and Fig. 1). Three patients (patients #2, #4, and 
#9) died due to esophageal perforation and tracheoesophageal 
fistula within 2 months after completion of re-RT. The acute 
dysphagia grades for pre- and post- re-irradiation were grade 
0–grade 0 in two patients, grade 0–grade 1 in one patient, 
grade 1–grade 1 in one patient, and grade 2–grade 2 in three 
patients. In patients #2, #4, and #9, the dysphagia grade 
after re-RT could not be evaluated because of acute severe 
complications (esophageal perforation and tracheoesophageal 
fistula). Late toxicities included grade 1 dysphagia (in patient 
#3). 
Discussion and Conclusion
Few reports exist concerning re-RT of recurrent esophageal 
cancer after primary radiotherapy plus esophagectomy [4]. 
In addition, few reports exist regarding re-RT of recurrent 
or persistent esophageal cancer after primary definitive 
radiotherapy (Table 4). In the present study, we evaluated 
the toxicities and clinical outcomes after re-RT of recurrent 
esophageal cancer after primary definitive radiotherapy.
  Yamaguchi et al. [11] reported 31 patients with recurrent 
or persistent esophageal cancer treated with 3D conformal 
re-RT (Table 4). Of the 31 patients, 14 underwent regional 
hyperthermia during the re-RT. The curative group (n = 11) 
was defined as patients without symptoms or who had mild 
dysphagia, without distant metastasis, and good performance. 
All other patients were classified into the palliative group. In 
the palliative group, severe esophageal toxicities were more 
common in the patients with advanced T stage (T3 or T4) at 
Fig. 1. Computed tomography images of at diagnosis (primary), 
at the time of recurrence, and treatment response of re-irradiation 
in three patients with tracheaesophageal fistula. 
Table 4. Summary of re-irradiation (re-RT) of esophagus after primary definitive (concurrent chemo-) radiotherapy
Author No.
Re-RT intervala) 
(mo)
Treatment at 
re-RT
Total dose of RTa) (Gy) CTx with 
re-RT, 
no. (%)
Toxicity over grade 3
non-hematologic 
(no.)
Survival 
time after 
re-RTa) (mo)Initial RT  Re-RT
Yamaguchi 
et al. [11]
Nonoshita 
et al. [12]
Teli et al. 
[13]
Harms et al. 
[10]
Cu: 11
 
Pa: 20
  6
34
16
10 (2-162)
3.3 (1.3-9.4)
Within 12 mo (47%)
15 (4-37)
3D-RT (±hyper-
thermia)
HDRB
3D-RT 
PDR
60 
(43.2-70.0)
60 
(40.0-80.4)
60
60-65
50 
(46-60)
40 
(36.0-65.2)
36 
(16.5-60.0)
20 
(20-32)
45-60
15-20
 11 
(100)
16 
(80)
  2 
(33)
NA
NA
EP (1)
EP (3), ES (1), EH (1), 
PE (1)
No severe toxicity
EH (4), ES (3), no TEF
TEF (2), FAB (1), ES (1)
Cu: 18.6
Pa: 6.5
30.0 
(14.4-35.8)
  7.9
8 
(4-19)
CTx, concurrent chemotherapy; Cu, curative group; Pa, palliative group; NA, not assessed; HDRB, high-dose-rate brachytherapy; PDR, 
pulsed dose rate brachytherapy; EP, esophageal perforation; ES, esophageal stricture; EH, esophageal hemorrhage; PE, pericardial effu-
sion; TEF, tracheoesophageal fistula; FAB, fatal arterial bleeding.
a) Values are presented as median (range). 
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the time of re-RT. 
  Nonoshita et al. [12] reported 6 patients with recurrent 
esophageal cancer after external radiotherapy (median dose, 
60 Gy). T stage at the time of primary radiotherapy and 
recurrence was T1 in all patients. Re-RT with high-dose-rate 
brachytherapy (HDRB) was performed once a week with a dose 
of 4 or 5 Gy per fraction (median total dose, 20 Gy). No toxicity 
was observed over grade 3. The median overall survival was 30 
months. 
  Teli et al. [13] reported a prospective and randomized study 
that included 34 patients who were palliated with re-RT and 
35 patients who refused re-RT and received peroral demand 
dilatation alone. Patients in the re-RT group showed better 
and more sustained improvement in their grade of dysphagia. 
The median overall survival period in the re-RT group was 7.9 
months compared with 3.1 months in the non-re-irradiated 
group. Six tracheoesophageal perforation cases were reported 
in the non-re-irradiated group, whereas no tracheoesophageal 
perforation was reported in the re-irradiated group. 
  In the Harms et al. [10] study, 16 patients with inoperable 
recurrence from esophageal cancer were re-irradiated using 
pulsed dose rate (PDR) brachytherapy. Patients treated with 
a weekly 5 Gy daytime schedule (0.5 Gy/pulse/hr, total dose 
15−20 Gy). After a median follow-up of 8 months, 3 patients 
showed a complete remission, and 5 showed a partial 
remission. Three patients with uncontrolled locoregional 
disease showed grade 4 complications (tracheoesophageal 
fistula, n = 2 or fatal arterial bleeding, n = 1).
  In the literatures, the median overall survival after re-
RT of recurrent esophageal cancer after primary definitive 
radiotherapy was 6.5–30.0 months [11,12] (Table 4). 
  In the present study, toxicities greater than grade 3 
(non-hematologic) were reported in 3 patients; fatal 
tracheoesophageal fistula and esophageal perforation. 
Other studies also reported tracheoesophageal fistula and 
esophageal perforation (Table 4). Yamaguchi et al. [11] reported 
that advanced T stage (T3 or T4) at the time of recurrence was 
significantly related to development of severe toxicities greater 
than grade 3 (p = 0.03). In the study of Nonoshita et al. [12], T 
stage at the time of recurrence was T1 in all patients (n = 6), 
and toxicities greater than grade 3 were not reported. 
  One re-RT study reported that all newly developed trache-
oesophageal fistulas (n = 3) after re-RT were the result of 
disease [15]. Harms et al. [10] reported that three patients (19%) 
presented with grade 4 complications (tracheoesophageal 
fistula, n = 2 or fatal arterial bleeding, n = 1), and all these 
patients suffered from uncontrolled locoregional disease. Thus, 
it remains unclear whether severe toxicity greater than grade 3 
is truly treatment-related or due to progressive disease [10].
  In the re-RT of recurrent esophageal cancer after primary 
radiotherapy, the total dose of re-RT, time interval between 
primary radiotherapy and re-RT, extent of disease progression, 
treatment modality, concurrent chemotherapy, recurred tumor 
T stage, and irradiated volume of esophagus can affect the 
toxicity.
   In conclusion, because of the small number of patients, it 
is difficult to generalize prognostic factors related to severe 
toxicity with re-RT. Re-RT of recurrent esophageal cancer after 
primary radiotherapy can cause severe toxicity. 
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